AbbVie and Genmab’s TEPKINLY approved by EC for advanced lymphoma

AbbVie and Genmab’s TEPKINLY approved by EC for advanced lymphoma

AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) have announced that the European Commission (EC) has granted conditional marketing authorization for TEPKINLY (epcoritamab), a groundbreaking therapy for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) following two or more prior treatments. This approval marks a significant milestone as TEPKINLY becomes the first and only […]

Bristol Myers Squibb CAR T cell therapy Breyanzi shows promising outcomes in clinical trials

Bristol Myers Squibb CAR T cell therapy Breyanzi shows promising outcomes in clinical trials

Bristol Myers Squibb (NYSE: BMY) has unveiled primary analysis results from the TRANSCEND FL clinical trial at the 2023 American Society of Hematology (ASH) Annual Meeting. This trial, part of a global, multicenter Phase 2 study, evaluates the efficacy of Breyanzi (lisocabtagene maraleucel, liso-cel) in patients with relapsed or refractory follicular lymphoma (FL). TRANSCEND FL: […]

Genentech bags Lunsumio FDA approval for R/R follicular lymphoma

Genentech bags Lunsumio FDA approval for R/R follicular lymphoma

Lunsumio FDA approval : Genentech, a subsidiary of the Roche Group, has secured the approval of the US Food and Drug Administration (FDA) for Lunsumio (mosunetuzumab-axgb) for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL) in adults, subjected to two or more treatments for their cancer. Lunsumio is a CD20xCD3 T-cell engaging bispecific […]

Ipsen to acquire American biopharma company Epizyme for $247m

Ipsen to acquire American biopharma company Epizyme for $247m

French pharma company Ipsen has agreed to acquire Epizyme, a Massachusetts-based commercial-stage biopharma company for an initial consideration of $247 million. Epizyme, which is listed on Nasdaq, is focused on developing and delivering therapies against novel epigenetic targets for patients with different types of cancer. Through the deal, Ipsen gets access to Tazverik (tazemetostat), the […]

Pfizer to acquire immuno-oncology company Trillium Therapeutics for $2.2bn

Pfizer to acquire immuno-oncology company Trillium Therapeutics for $2.2bn

US pharma giant Pfizer has agreed to acquire Trillium Therapeutics, a publicly listed Canadian clinical stage immuno-oncology company, for $18.5 per share or $2.26 billion in an all-cash deal. The portfolio of Trillium Therapeutics has biologics that have been designed to boost the ability of patients’ innate immune systems for detecting and killing cancer cells. […]

Epizyme gets FDA priority review for TAZVERIK in follicular lymphoma

Epizyme gets FDA priority review for TAZVERIK in follicular lymphoma

Epizyme has been granted priority review by the US Food and Drug Administration (FDA) for the use of TAZVERIK (tazemetostat) in relapsed or refractory follicular lymphoma (FL). As per the new drug application (NDA) that has been accepted by the FDA, the Massachusetts-based biopharma company is seeking the accelerated approval of the methyltransferase inhibitor for […]

Nordic Nanovector begins Phase 1b trial of Betalutin and Rituximab combo for follicular lymphoma

Nordic Nanovector begins Phase 1b trial of Betalutin and Rituximab combo for follicular lymphoma

Nordic Nanovector has commenced the dosing of the first patient in its Phase 1b clinical trial, dubbed Archer-1, which aims to evaluate the combination of its investigational lymphoma drug Betalutin (177Lu-satetraxetan-lilotomab) with Roche’s rituximab (RTX) as a second-line treatment for follicular lymphoma (2L FL). This trial is a critical step in exploring novel treatments for […]

Nordic Nanovector launches US Phase 2b trial for Betalutin in follicular lymphoma

Nordic Nanovector launches US Phase 2b trial for Betalutin in follicular lymphoma

Nordic Nanovector, a Norwegian biopharmaceutical company, has commenced the first clinical site in the United States for its PARADIGME trial. This pivotal trial is designed to assess the efficacy of Betalutin (lilotomab), an innovative anti-CD37 antibody, in treating third-line (3L) follicular lymphoma patients who have previously failed anti-CD20 therapies. PARADIGME Trial Marks a Significant Milestone […]